Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay
21.04.2014 / Fierce Pharma
Last week, generics makers asked the Supreme Court to let them launch their copies of Teva's Copaxone while it hears the Israeli company's appeal over the drug's patents. Now, they'll likely get that chance. Chief Justice John Roberts rejected Teva's bid to block competition until the court clash wraps, meaning generics could hit as soon as next month.